Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30196% above fair value

$11.62+0.72 (+6.61%)

Close on Nov 13, 2026Market cap $407.48MP/E 387.3Yield –

Fennec Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Fennec Pharmaceuticals's gross margin for the twelve months ending Dec 31, 2023 was 94.1%. For fiscal 2023 it was 94.1%, against 94.4% the year before.

Annual gross margin

Period	Period end	Value	Change (pts)
FY2023	Dec 31, 2023	94.1%	−0.3
FY2022	Dec 31, 2022	94.4%	–

Quarterly gross margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q4 FY2023	Dec 31, 2023	93.0%	–
Q3 FY2023	Sep 30, 2023	94.9%	–
Q2 FY2023	Jun 30, 2023	95.5%	–
Q1 FY2023	Mar 31, 2023	94.3%	–

Where these numbers come from

Parsed from the XBRL in Fennec Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3 reverse split on Nov 13, 2014
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing